There are numerous diseases that are claimed to have a correlation with ABO blood groups. The association with malignancy, especially with exocrine pancreas malignancy, has been documented. Analysis on distribution of blood groups in primary brain tumors and clinical value has revealed conflicting results. Here we aimed to evaluate the association between blood groups and glial neoplasia.
Patients admitted between 2000–2013 and had a diagnosis of glial neoplasia were evaluated. Documented blood groups were analyzed and compared with the National blood group data obtained from Turkish Red Crescent Society. The prognostic significance of ABO blood groups was analyzed within glioblastoma multiforme (GBM), anaplastic astrocytoma and grade 1-2 astrocytoma.
759 patients with a diagnosis of glial neoplasia were evaluated. Distribution of ABO blood groups in the different grades of glial neoplasia was similar with the national blood group frequencies. There was no statistically significant difference between all grades of glial neoplasia and healthy control patients. Median overall survival (mOS) of GBM patients are 12.9, 13.4, 5.7, 12.8 months in A, B, AB, and O blood groups, respectively (p = 0.46). mOS of anaplastic astrocytoma patients are 24.4, 47.2, 37.8, 29.2, 25.7 months, respectively (p = 0.96). mOS in grade1-2 astrocytoma in different blood groups are similar (p = 0.80).
In our small patient group, when compared with general population, there seems to be no association between frequencies of ABO blood groups and glial neoplasia. The ABO blood groups have no prognostic impact on glial neoplasia.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.